MX2016016667A - Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer. - Google Patents

Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.

Info

Publication number
MX2016016667A
MX2016016667A MX2016016667A MX2016016667A MX2016016667A MX 2016016667 A MX2016016667 A MX 2016016667A MX 2016016667 A MX2016016667 A MX 2016016667A MX 2016016667 A MX2016016667 A MX 2016016667A MX 2016016667 A MX2016016667 A MX 2016016667A
Authority
MX
Mexico
Prior art keywords
cancer
methods
drug resistance
treating cancer
preventing
Prior art date
Application number
MX2016016667A
Other languages
English (en)
Inventor
Classon Marie
Guler Gulfem
Pitti Robert
Philippe Stephan Jean-
Albert Tindell Charles
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2016016667A publication Critical patent/MX2016016667A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan aquí métodos para usar antagonistas de G9a, para tratar cáncer y/o prevenir la resistencia a fármacos en un individuo. Por ejemplo, se proporciona un método para tratar cáncer en un individuo que comprende administrar al individuo un antagonista de G9a solo o en combinación con un agente de terapia de cáncer. En algunas modalidades, el antagonista de G9a incrementa el periodo de sensibilidad al cáncer y/o retrasa el desarrollo de resistencia al cáncer.
MX2016016667A 2014-06-23 2015-06-23 Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer. MX2016016667A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462015932P 2014-06-23 2014-06-23
PCT/US2015/037189 WO2015200329A1 (en) 2014-06-23 2015-06-23 Methods of treating cancer and preventing cancer drug resistance

Publications (1)

Publication Number Publication Date
MX2016016667A true MX2016016667A (es) 2017-08-21

Family

ID=54938739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016667A MX2016016667A (es) 2014-06-23 2015-06-23 Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.

Country Status (10)

Country Link
US (1) US20170209444A1 (es)
EP (1) EP3157524A4 (es)
JP (1) JP2017519017A (es)
KR (1) KR20170017996A (es)
CN (1) CN106456627A (es)
BR (1) BR112016030064A2 (es)
CA (1) CA2952474A1 (es)
MX (1) MX2016016667A (es)
RU (1) RU2017101809A (es)
WO (1) WO2015200329A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519393B1 (en) 2016-09-30 2022-05-18 Epizyme Inc Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3612181A4 (en) * 2017-04-21 2021-01-06 Epizyme, Inc. COMBINATION THERAPIES WITH EHMT2 INHIBITORS
SG11202003225YA (en) * 2017-10-18 2020-05-28 Epizyme Inc Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137516A1 (en) * 2007-11-05 2009-05-28 Wyeth Compositions and methods of treating dyslipidemia

Also Published As

Publication number Publication date
WO2015200329A1 (en) 2015-12-30
BR112016030064A2 (pt) 2017-08-22
US20170209444A1 (en) 2017-07-27
RU2017101809A (ru) 2018-07-23
JP2017519017A (ja) 2017-07-13
CN106456627A (zh) 2017-02-22
EP3157524A1 (en) 2017-04-26
EP3157524A4 (en) 2017-12-06
CA2952474A1 (en) 2015-12-30
KR20170017996A (ko) 2017-02-15

Similar Documents

Publication Publication Date Title
ZA201806633B (en) Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
MX2017003933A (es) Metodos de tratamiento de la enfermedad hepatica.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
IL249133A0 (en) A method of treating cancer with antagonists against pd-1 and pd-l1 in combination with radiation therapy
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
MX2016002273A (es) Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
NZ731467A (en) Anti-tim3 antibodies and methods of use
MY187540A (en) Compounds active towards bromodomains
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
GB2538682A (en) Nasal drug products and methods of their use
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2016016667A (es) Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.
EP3325100A4 (en) COMBINED THERAPY USING PDK1 AND PI3K INHIBITORS
MY175326A (en) Product and method for treating diarrhea
PH12017501979A1 (en) Pharmaceutical compound
EP3508123A4 (en) METHOD FOR EVALUATING THE THERAPEUTIC EFFECT OF A MEDICINAL PRODUCT IN A CANCER PATIENT, METHOD FOR PRODUCING THERAPEUTIC EFFECT EVALUATION DATA, DEVICE FOR EVALUATING THERAPEUTIC EFFECT, AND EVALUATION PROGRAM THERAPEUTIC EFFECT
NZ725067A (en) Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі
UA84195U (ru) Способ лечения гриппа у взрослых
MX2017001512A (es) Compuestos activos hacia bromodominios.
UA91892U (uk) Спосіб неспецифічної профілактики та лікування кліщового вірусного енцефаліту